These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
924 related articles for article (PubMed ID: 9650898)
1. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC). Liu MT; Yeh CY Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898 [TBL] [Abstract][Full Text] [Related]
2. Prognostic implication of pretreatment titer of serum immunoglobulin A against Epstein-Barr virus capsid antigen in nasopharyngeal carcinoma patients in Sihui, Guangdong. Ling W; Cao SM; Huang QH; Li YH; Deng MQ Ai Zheng; 2009 Jan; 28(1):57-9. PubMed ID: 19448418 [TBL] [Abstract][Full Text] [Related]
3. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma. Twu CW; Wang WY; Liang WM; Jan JS; Jiang RS; Chao J; Jin YT; Lin JC Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):130-7. PubMed ID: 16979842 [TBL] [Abstract][Full Text] [Related]
5. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma. Chang KP; Hsu CL; Chang YL; Tsang NM; Chen CK; Lee TJ; Tsao KC; Huang CG; Chang YS; Yu JS; Hao SP Oral Oncol; 2008 Aug; 44(8):784-92. PubMed ID: 18206420 [TBL] [Abstract][Full Text] [Related]
6. Analyses of the prognostic significance of the Epstein-Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma. Dardari R; Menezes J; Drouet E; Joab I; Benider A; Bakkali H; Kanouni L; Jouhadi H; Benjaafar N; El Gueddari B; Hassar M; Khyatti M J Clin Virol; 2008 Feb; 41(2):96-103. PubMed ID: 18024156 [TBL] [Abstract][Full Text] [Related]
7. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, tonsillar carcinoma and control groups. Oberender H; Nowak R; Donner A; Kunkel M; Gärtner L; Scholtz HJ Acta Virol; 1983 May; 27(3):277-81. PubMed ID: 6138990 [TBL] [Abstract][Full Text] [Related]
8. [Prognostic impact of plasma Epstein-Barr virus DNA concentration on distant metastasis in nasopharyngeal carcinoma]. Hou X; Zhang L; Zhao C; Li S; Lu LX; Han F; Shao JY; Huang PY Ai Zheng; 2006 Jul; 25(7):785-92. PubMed ID: 16831265 [TBL] [Abstract][Full Text] [Related]
9. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen. Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466 [TBL] [Abstract][Full Text] [Related]
10. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Leung SF; Chan AT; Zee B; Ma B; Chan LY; Johnson PJ; Lo YM Cancer; 2003 Jul; 98(2):288-91. PubMed ID: 12872347 [TBL] [Abstract][Full Text] [Related]
11. Outcome of patients with positive Epstein-Barr virus serologic status in the absence of nasopharyngeal carcinoma in Hong Kong. Lo S; Ho WK; Wei WI Arch Otolaryngol Head Neck Surg; 2004 Jun; 130(6):770-2. PubMed ID: 15210561 [TBL] [Abstract][Full Text] [Related]
12. The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC). Levine PH; Pearson GR; Armstrong M; Bengali Z; Berenberg J; Easton J; Goepfert H; Henle G; Henle W; Heffner D; Huang A; Hyams VJ; Lanier A; Neel HB; Pilch B; Pointek N; Taylor W; Terebelo H; Weiland L Cancer Detect Prev; 1981; 4(1-4):307-12. PubMed ID: 6299561 [TBL] [Abstract][Full Text] [Related]
13. [Immunoglobulin A serum antibodies against the capsid antigen of Epstein-Barr virus in the differential diagnosis and follow-up of nasopharyngeal cancer]. Pavelka R; Popow-Kraupp T; Radaszkiewicz T Wien Klin Wochenschr; 1985 Jul; 97(14):588-95. PubMed ID: 2996246 [TBL] [Abstract][Full Text] [Related]
14. Nasopharyngeal carcinoma: the diagnostic value of the antibody-dependent, cellular cytotoxicity test and of EBV serology. Faggioni A; Corradini C; Venanzoni M; Cardi G; Bevere F; Barile G; Zompetta C; Frati L J Exp Pathol; 1987; 3(4):471-7. PubMed ID: 2842480 [TBL] [Abstract][Full Text] [Related]
15. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma. Shao JY; Huang XM; Yu XJ; Huang LX; Wu QL; Xia JC; Wang HY; Feng QS; Ren ZF; Ernberg I; Hu LF; Zeng YX Anticancer Res; 2001; 21(4B):3021-9. PubMed ID: 11712805 [TBL] [Abstract][Full Text] [Related]
16. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia. Karray H; Ayadi W; Fki L; Hammami A; Daoud J; Drira MM; Frikha M; Jlidi R; Middeldorp JM J Med Virol; 2005 Apr; 75(4):593-602. PubMed ID: 15714486 [TBL] [Abstract][Full Text] [Related]
17. Long-term prognostic effects of plasma epstein-barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy. Lin JC; Wang WY; Liang WM; Chou HY; Jan JS; Jiang RS; Wang JY; Twu CW; Liang KL; Chao J; Shen WC Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1342-8. PubMed ID: 17449194 [TBL] [Abstract][Full Text] [Related]
18. [Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma]. Cao SM; Min HQ; Gao JS; Hong MH; Xiao XB; Zhang CQ; Liu XD; Zhang AL; Guo X Ai Zheng; 2003 Mar; 22(3):302-6. PubMed ID: 12654192 [TBL] [Abstract][Full Text] [Related]
19. [Significance of detection of serum sialic acid and Epstein-Barr virus VCA-IgA in diagnosis and monitoring radiotherapy effectiveness in nasopharyngeal carcinoma patients]. Jiang LN; Dai LC; He JF; Chen YW; Ma ZH Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):30-2. PubMed ID: 16816858 [TBL] [Abstract][Full Text] [Related]
20. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening. Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]